| Identification | Back Directory | [Name]
BTO-1 | [CAS]
40647-02-7 | [Synonyms]
BTO-1
Polo-like Kinase Inhibitor II, BTO-1
5-Cyano-7-nitro-2-benzothiazolecarboxamide-3-oxide
2-Benzothiazolecarboxamide, 5-cyano-7-nitro-, 3-oxide
Polo-like Kinase Inhibitor II, BTO-1 - CAS 40647-02-7 - Calbiochem | [Molecular Formula]
C9H4N4O4S | [MDL Number]
MFCD11045282 | [MOL File]
40647-02-7.mol | [Molecular Weight]
264.22 |
| Chemical Properties | Back Directory | [Boiling point ]
553.0±60.0 °C(Predicted) | [density ]
1.89±0.1 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
H2O: <2ML/mL | [form ]
solid | [pka]
14.67±0.30(Predicted) | [color ]
tan | [Water Solubility ]
H2O: <2mL/mL
DMSO: ≥5mg/mL |
| Hazard Information | Back Directory | [Uses]
BTO-1 is a benzothiazolo-N-oxide Plk1 inhibitor. | [General Description]
A cell-permeable benzothiazolo-N-oxide compound that targets the ATP-binding pocket of polo-like kinase and is shown to inhibit Plk1 kinase activity in cell-free kinase assays (IC50 = 8.0 μM) and suppress the phosphorylation of cellular Plk1 substrate Cdc25C in rat kangaroo kidney-derived PTK cells (75% inhibition at 6.3 μM). BTO-1 treatment of cultured cells results in mitosis defects consistent with loss-of-Plk1 phenotypes seen in Plk1 RNAi-treated U20S cells, including the appearance of monopolar spindles and the reduction of γ-tubulin at the centrosomes. Plk1 inhibition by BTO-1 in HeLa cells results in a blockage of Rho and Rho-GEF recruitment, which is essential for the assembly of a functional contractile ring. | [Biochem/physiol Actions]
BTO-1 is a polo-like kinase (Plk) inhibitor. |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
Sigma-Aldrich
|
| Tel: |
021-61415566 800-8193336 |
| Website: |
https://www.sigmaaldrich.cn |
| Company Name: |
Merck KGaA
|
| Tel: |
(+86) 21 2033 8288 |
| Website: |
http://www.sigmaaldrich.cn |
|